Clinical Evidence Synthesis Plan for Formulary Review

Role: Senior Health Technology Assessment (HTA) Specialist and Clinical Evidence Synthesist with 15+ years in formulary dossier preparation.

Context

• Target Drug Candidate: {{target_drug_candidate}}
• Target Therapeutic Indication: {{therapeutic_indication}}
• Standard of Care Comparators: {{standard_of_care_comparators}}
• Primary Clinical Endpoints: {{primary_endpoints}}
• Target P&T Committee / Payer Body: {{target_pt_committee}}
• Target Submission Deadline: {{submission_deadline}}

Task

Synthesize the evidentiary landscape for {{target_drug_candidate}} against {{standard_of_care_comparators}} in {{therapeutic_indication}}, delivering a comprehensive clinical evidence synthesis plan to guide the final dossier preparation for {{target_pt_committee}} by {{submission_deadline}}.

Method

1. Define search parameters and inclusion criteria across randomized controlled trials (RCTs), real-world studies, and network meta-analyses covering {{therapeutic_indication}}.
2. Extract and reconcile disparate data definitions for {{primary_endpoints}} across {{target_drug_candidate}} and {{standard_of_care_comparators}}.
3. Establish a risk-of-bias evaluation framework (e.g., Cochrane RoB 2, ROBINS-I) calibrated to the selected study archetypes.
4. Structure indirect treatment comparison (ITC) and network meta-analysis (NMA) methodologies where head-to-head clinical data is missing.
5. Categorize safety and tolerability profiles into a comparative risk matrix highlighting number needed to harm (NNH) and serious adverse events.
6. Formulate subpopulation synthesis tracks to evaluate differential efficacy across high-risk patient segments.
7. Map synthesized findings directly to {{target_pt_committee}} appraisal criteria and value framework requirements.
8. Establish the analytical workflow, resource allocation, and milestone timelines needed prior to {{submission_deadline}}.

Constraints

• MUST structure all quantitative synthesis recommendations in accordance with PRISMA-NMA guidelines.
• MUST NOT draw clinical superiority conclusions without explicitly defining the statistical threshold or ITC feasibility.
• Every evidence stream MUST explicitly address {{primary_endpoints}} and comparator performance.
• Limit recommendations to peer-reviewed, regulatory-grade, or clinical study report (CSR) evidence types.

Output format

Provide the synthesis plan in 4 numbered sections:

1. Evidence Scoping & Search Strategy (max 250 words)
2. Quantitative Synthesis & Data Reconciliation Plan (bulleted methodology including ITC/NMA approach)
3. Comparative Safety & Subpopulation Framework (table or structured list of risk endpoints)
4. Synthesis Execution Milestones & Timeline (phased operational schedule targeting {{submission_deadline}})

Self-review

• Confirm all 6 context variables are explicitly addressed throughout the synthesis steps.
• Verify that both safety and efficacy synthesis streams have distinct evaluation criteria.
• Ensure no conclusive clinical claims are made without specifying the necessary comparative analytical method.